reated patients (sPsel 38.six [24.8- 60.9], P = 0.181 and PAC1-ADP 90.7 [23.166.1], P = 0.784). Splenectomized sufferers tended towards increased sPsel-levels when compared to nonsplenectomized (46.4 [30.40.6] and 30.six [17.6- 50.4], P = 0.056). Past thrombosis had no effect on sPsel-levels or platelet activation markers. Bleeding severity, assessed through the ISTH-ITP-BAT showed a weak correlation with unactivated CD62P (= 0.34, P = 0.016), whereas there was no correlation with sPsel or other parameters of platelet exercise. TABLE one Patientsclinical and laboratory characteristicsITP n Gender, female Existing ITP remedy none Corticosteroids TPO-RA others Preceding thrombosis Splenectomy Age, years Platelet count, x10/L Duration of disorder, months BS SMOG-Index, complete 50 50 n 51 51 51 51 51 n1 35 33 six 9 three 4 twelve median 47 77 113 2 68.six 64.seven eleven.8 17.seven five.9 eight 24 255 percentile 325 4139 4062 0 18 18 n 18 18 18 18 3 0 median 59 60 na two sixteen.seven 0 255 percentile 462 216 na 1 TPC n 18 18 n1 9 Na 50 naFIGURE one Comparison of sP-selectin (ng/ml) and unactivated CD62P MFI (median fluorescence intensity) in between ITP individuals and non-immunological thrombocytopenic controls (TPC)Conclusions: ITP-patients have greater sPsel, IL-15 Inhibitor Source specifically underneath TPO-RA-treatment, whereas there was no clear pattern of platelet hyperreactivity. There was no association or correlation of platelet activation markers with preceding thrombosis or bleeding severity.610 of|ABSTRACTPB0823|Switching from Eltrombopag or Romiplostim to Avatrombopag in Immune Thrombocytopenia: A Multicenter Examine of U.S. ITP Referral Centers H. Al-Samkari1,2; D. IL-10 Inhibitor review Jiang3,four; T. Gernsheimer3,four; H. Liebman5; S. Lee5; M. Wojdyla6; M. Vredenburg6; A. CukerMassachusetts Basic Hospital, Boston, United states; 2Harvard MedicalSchool, Boston, U.s.; 3University of Washington, Seattle, United states of america; 4Seattle Cancer Care Alliance, Seattle, U.s.; 5University of Southern California, Los Angeles, United states of america; 6Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum, Durham, United states of america; 7University of Pennsylvania, Philadelphia, United states of america FIGURE one Median platelet counts for every patient just before switch Background: Avatrombopag is definitely an oral thrombopoietin receptor agonist (TPO-RA) authorized for remedy of immune thrombocytopenia (ITP). Information describing effectiveness of avatrombopag following remedy with other TPO-RAs is limited. Aims: Assess ITP treatment method outcomes in patients switching from eltrombopag/romiplostim to avatrombopag. Approaches: We retrospectively evaluated all grownups with ITP switched from eltrombopag or romiplostim to avatrombopag at four U.S. tertiary ITP referral centers from July 2019 as a result of December 2020 who were treated with avatrombopag for 2 months. Outcomes: 45 sufferers have been incorporated, using a median (selection) age of 60 (217) many years; 53 were female. Mean avatrombopag treatment duration was 9 months. At avatrombopag initiation, sufferers had ITP to get a suggest of eight.3 many years which has a imply (array) of 4.8 (20) prior ITP solutions. The reason for switching to avatrombopag was ease in 51 , ineffectiveness of romiplostim/eltrombopag in 31 , and adverse occasion on romiplostim/eltrombopag in 18 . Platelet Outcomes: In all patients, the median platelet count (Plt) on eltrombopag or romiplostim was 4509/L vs. 11409/L on avatrombopag (P 0.0001); in individuals switched for ineffectiveness of romiplostim/eltrombopag, it had been 2809/L on romiplostim/ eltrombopag vs. 8809/L on avatromb